| 1. | Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin, 2012, 62(6): 394-399. | 
				                                                        
				                                                            
				                                                                | 2. | Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer, 2021, 10(3): 181-223. | 
				                                                        
				                                                            
				                                                                | 3. | Song T. Recent advances in surgical treatment of hepatocellular carcinoma. Drug Discov Ther, 2015, 9(5): 319-330. | 
				                                                        
				                                                            
				                                                                | 4. | Wang YY, Zhong JH, Su ZY, et al. Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. Br J Surg, 2016, 103(6): 725-734. | 
				                                                        
				                                                            
				                                                                | 5. | 魏永健, 任龍飛, 張磊, 等. 術前血小板與淋巴細胞比值對肝癌切除術后患者預后價值的Meta分析. 中國普通外科雜志, 2021, 30(1): 44-54. | 
				                                                        
				                                                            
				                                                                | 6. | 張瑜, 陳琨. 血小板4項參數聯合血清AFP水平檢測對乙型肝炎肝硬化肝癌的診斷價值研究. 國際檢驗醫學雜志, 2020, 41(23): 2921-2924. | 
				                                                        
				                                                            
				                                                                | 7. | Dai T, Deng M, Ye L, et al. Prognostic value of combined preoperative gamma-glutamyl transpeptidase to platelet ratio and fibrinogen in patients with HBV-related hepatocellular carcinoma after hepatectomy. Am J Transl Res, 2020, 12(6): 2984-2997. | 
				                                                        
				                                                            
				                                                                | 8. | Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med, 1996, 15(4): 361-387. | 
				                                                        
				                                                            
				                                                                | 9. | Kramer AA, Zimmerman JE. Assessing the calibration of mortality benchmarks in critical care: The Hosmer-Lemeshow test revisited. Crit Care Med, 2007, 35(9): 2052-2056. | 
				                                                        
				                                                            
				                                                                | 10. | Huitzil-Melendez FD, Capanu M, O’Reilly EM, et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol, 2010, 28(17): 2889-2895. | 
				                                                        
				                                                            
				                                                                | 11. | 于瀟, 武國兵, 張愛斌, 等. 血小板在肝細胞癌發生發展中的作用. 臨床肝膽病雜志, 2022, 38(6): 1426-1430. | 
				                                                        
				                                                            
				                                                                | 12. | 楊思維, 張致遠, 蘇天昊, 等. 肝纖維化血清學模型預測HBV相關肝細胞癌經肝動脈化療栓塞序貫射頻消融后復發. 中國介入影像與治療學, 2021, 18(8): 449-454. | 
				                                                        
				                                                            
				                                                                | 13. | 董菁菁, 王允野, 劉昆, 等. γ-谷氨酰轉肽酶和血小板比值指數對慢性乙型肝炎肝纖維化的診斷價值. 中華傳染病雜志, 2017, 35(11): 670-674. | 
				                                                        
				                                                            
				                                                                | 14. | Kim JH, Kim JW, Seo JW, et al. Noninvasive tests for fibrosis predict 5-year mortality and hepatocellular carcinoma in patients with chronic hepatitis B. J Clin Gastroenterol, 2016, 50(10): 882-888. | 
				                                                        
				                                                            
				                                                                | 15. | 梅寶富, 鄧志鋒, 鄭蘭, 等. γ-谷氨酰轉肽酶和血小板比值對肝癌介入術后急性肝功能惡化的預測作用. 肝臟, 2021, 26(2): 175-178. | 
				                                                        
				                                                            
				                                                                | 16. | Kim MN, Lee JH, Chon YE, et al. Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy. Eur J Gastroenterol Hepatol, 2020, 32(3): 433-439. | 
				                                                        
				                                                            
				                                                                | 17. | Kunutsor SK. Gamma-glutamyltransferase—friend or foe within? Liver Int, 2016, 36(12): 1723-1734. | 
				                                                        
				                                                            
				                                                                | 18. | 郭鴻雁, 劉慶峰. γ-谷氨酰轉肽酶、高爾基體蛋白73及甲胎蛋白檢測對早期原發性肝癌的診斷價值. 癌癥進展, 2019, 17(11): 1332-1334, 1350. | 
				                                                        
				                                                            
				                                                                | 19. | 高海鋒, 趙秋劍. 血清AFP、5’-NT和GGT聯合檢測在肝細胞癌早期診斷中的應用價值. 山西醫科大學學報, 2015, 46(2): 115-118. | 
				                                                        
				                                                            
				                                                                | 20. | Zhang R, Guo H, Xu J, et al. Activated platelets inhibit hepatocellular carcinoma cell differentiation and promote tumor progression via platelet-tumor cell binding. Oncotarget, 2016, 7(37): 60609-60622. | 
				                                                        
				                                                            
				                                                                | 21. | 尹天圣, 易亞陽, 毛熙賢, 等. 肝癌肝切除術后肝衰竭危險因素的Meta分析. 臨床肝膽病雜志, 2014, 30(10): 1009-1014. | 
				                                                        
				                                                            
				                                                                | 22. | 孫雅軒. 微血管侵犯與肝細胞癌預后的關系的臨床研究. 長春: 吉林大學, 2017. | 
				                                                        
				                                                            
				                                                                | 23. | Lee DH. Editorial for “Nomogram predicting vessels encapsulating tumor clusters in hepatocellular carcinoma from preoperative gadoxetate-enhanced MRI: a multicenter study”. J Magn Reson Imaging, 2022 Oct 25. doi: 10.1002/jmri.28489. | 
				                                                        
				                                                            
				                                                                | 24. | 趙杰, 焦宇文, 錢峻, 等. 肥胖癥患者腹腔鏡袖狀胃切除術后體質量反彈的危險因素分析及列線圖模型的構建. 中華胃腸外科雜志, 2022, 25(10): 913-920. |